Treatment of AL Amyloidosis with Congestive Heart Failure (Cardiac Involvement)
Congestive heart failure resulting from cardiac involvement is a distinct and therapeutically challenging presentation of AL amyloidosis. The hemodynamic instability characteristic of this scenario narrows the range of agents that can safely be used.
Clinical Scenario
In AL amyloidosis with congestive heart failure (cardiac involvement), many standard heart failure agents are poorly tolerated. Renin-angiotensin system blockers and beta blockers tend to exacerbate hypotension and suppress the compensatory sinus tachycardia, respectively, contributing to worsened hemodynamic instability and increased morbidity and mortality in this population.
Treatment Approach
Management centres on fluid balance, with diuretic-based therapy forming the mainstay of supportive care in this setting. The complete evidence-based regimen — including specific agent selection, sequencing, and individualised considerations — is available in the structured protocol below.
References
DOI: 10.1200/OP.22.00396
In patients with congestive heart failure from AL amyloidosis, standard-of-care therapy agents such as renin-angiotensin system blockers and beta blockers are poorly tolerated as they exacerbate hypotension and suppress the compensatory sinus tachycardia, respectively, leading to hemodynamic instability and therefore to increased morbidity and mortality.
The use of loop diuretics (eg, furosemide) with aldosterone antagonists (eg, spironolactone) is usually the mainstay of therapy, with sometimes the addition of midodrine to improve hypotension.
View source ↗